HEM Pharma Inc.: debt-to-equity, ROE and more
KOSDAQ, Legal name HEM Pharma Inc.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 894.0%
- Equity ratio
- 10.1%
- ROE
- -454.9%
- Op. margin
- -120.1%
- Rev. growth
- -13.9%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | 26.9% | 78.8% | -51.3% | -589.8% | n/a |
| FY2022 separate | 72.2% | 58.1% | -64.3% | -361.0% | 97.5% |
| FY2023 separate | 60.1% | 62.5% | -67.1% | -220.1% | 45.7% |
| FY2024 separate | 41.1% | 70.9% | -29.3% | -51.0% | 181.9% |
| FY2025 consolidated | 894.0% | 10.1% | -454.9% | -120.1% | -13.9% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩1.9B | ₩3.7B | ₩5.3B | ₩15.1B | ₩13.0B |
| Operating profit | -₩11.0B | -₩13.2B | -₩11.8B | -₩7.7B | -₩15.6B |
| Pre-tax income | -₩10.9B | -₩13.0B | -₩11.7B | -₩7.6B | -₩23.7B |
| Net income | -₩10.9B | -₩13.0B | -₩11.7B | -₩7.6B | -₩23.7B |
| Total assets | ₩27.0B | ₩34.8B | ₩27.8B | ₩36.9B | ₩51.8B |
| Total liabilities | ₩5.7B | ₩14.6B | ₩10.4B | ₩10.7B | ₩46.6B |
| Total equity | ₩21.3B | ₩20.2B | ₩17.4B | ₩26.1B | ₩5.2B |
| Paid-in capital | ₩2.7B | ₩3.0B | ₩3.1B | ₩3.5B | ₩3.6B |
| Debt/equity (source value) | 26.9% | 72.2% | 60.1% | 41.1% | 894.0% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2016-12-30
- Listed
- 24/11/05
- Employees
- 101
- Auditor
- 대주회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1717110129857
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for HEM파마Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.